

CSL
2023 Research Acceleration Initiative

February 2023

Dr Marthe D'Ombrain
Senior Director & Head,
Global Research Innovation

Legal Notice

The information provided in this document is provided “as is” without warranty of any kind; either express or implied, and is intended for informational purposes only. The information contained herein is subject to change at any time without notice.

In no event shall CSL Limited be liable for any direct, indirect, special or consequential damages or any damages whatsoever resulting from loss of use, data, or profits arising out of or in connection with the use of this information.

AGENDA

Overview of CSL

Areas of interest for collaboration

CSL Research Acceleration Initiative

Benefits of collaborating with CSL

CSL's core Therapeutic Areas

Questions

Overview of CSL

Our Businesses



CSL Behring

Biotherapies & Rare Disease

CSL Plasma

Plasma Donation

CSL Seqirus

Vaccines

CSL Vifor

Iron Deficiency & Nephrology*

Driven by Our Promise

* CSL will follow the required legal processes of formally changing the names for Vifor Pharma and Seqirus entities in due course.

CSL at a Glance

40+

Countries of operations around the world

US$10.6

Billion in annual revenue

US$4.6

Billion in R&D investments in the last 5 years to advance product pipeline

30,000+

Employees around the world

2000+

R&D employees

330+

Plasma collection centres across China, Europe and North America

Our Locations



Top 25 Biotech Companies of 2022

GEN Genetic Engineering & Biotechnology News

Rank	Company	Ticker Symbol	Market Cap (US$ Billion)
1	Novo Nordisk	NOVO-B (CPH)	236.0
2	Thermo Fisher Scientific	TMO (NASD)	213.4
3	Amgen	AMGN (NASD)	130.8
4	**CSL Ltd**	**CSL (ASX)**	**92.2 B**
5	Gilead Sciences Inc	GILD (NASD)	77.6
6	Regeneron Pharmaceuticals Inc	REGN (NASD)	67.4
7	Vertex Pharmaceuticals	VRTX (NASD)	61.5
8	Moderna	MRNA (NASD)	58.7
9	Chugai Pharmaceutical	4519 (JPX)	52.6
10	Illumina	ILMN (NASD)	50.9
11	Lonza	LONN (SWX)	49.2
12	WuXi AppTec	603259 (SHSE)	47.9
13	Samsung Biologics	207940 (KRX)	42.2
14	Agilent Technologies	A (NYSE)	40.3
15	Jiangsu Hengrui Medicine Co Ltd	600276 (SHSE)	40.1
16	BioNTech SE	BNTX (NASD)	33.4
17	WuXi Biologics	2269 (HKG)	33.3
18	Biogen	BIIB (NASD)	30.8
19	Sun Pharmaceutical Industries	SUNPHARMA (NSE)	26.1
20	Seagan	SGEN (NASD)	23.9

https://www.genengnews.com/a-lists/top-25-biotech-companies-of-2022

Research Acceleration Initiative

CSL's Research Acceleration Initiative

Objective: to build relationships with entrepreneurial researchers and fastrack discovery of innovative medicines that address unmet needs

Focus on early stage projects in specific areas aligned with CSL's Therapeutic Areas

Why? Early collaborations with high quality academic partners are key to building a sustainable pipeline

CSL has a strong interest in supporting local medical research efforts and strengthening POC capability in the regions in which we work

- ✓ Successful applicants receive up to AUD 250k p.a. for up to 2 years (maximum AUD 500,000 for 2 year project)
- ✓ CSL scientific champions assigned to each project to provide expert, industry guidance

CSL 2023 Research Acceleration Initiative Process



No limitation on number of abstracts each registered organisation or individual researcher can submit

Agreement Guidance

Separate collaboration agreements will be negotiated for each project which reflect the nature of the project, nature of funding and support, and the contributions of both parties

Under these negotiated agreements, CSL will be granted certain rights of interest to the program results for further R&D and/or commercialisation

Collaboration agreements will typically include the following terms (although CSL may propose other conditions depending on the nature of the project):

- *Research organisation will own results arising under the project*
  - CSL would typically own any results which relate to proprietary CSL products or materials if they are contributed to the project
  - The RAI is designed to accelerate the translation of novel discoveries made by research scientists – for proposals outside this scope, we may propose that projects be progressed outside the RAI
- *CSL will be granted an exclusive option to negotiate an exclusive, worldwide licence*
- *CSL supports publication of research outcomes*

Further details on agreement terms can be provided on request

Eligibility

To be eligible to apply, researchers/clinicians must satisfy the following 2 conditions:

1. Be employed by a research organisation registered to participate in the 2023 Research Acceleration Initiative

2. Submit a 300 word online abstract that is aligned with CSL's Therapeutic Areas and scientific Platforms:



Specific indications of focus for each TA are provided on slides 22-28

Abstract submission via online portal

Step 1/2 - Lead Investigator Information

Applications for the 2023 CSL Research Acceleration Initiative open 3rd January 2023 and close 23rd February 2023. Applications received outside these dates (before or after) will not be reviewed.

Fields with * are mandatory

First Name *

Salutation

Last Name *

Job Title *

Organization *

Phone

Email *

Confirm Email *

Address

City

Zip/Postcode

Country *

Geographical region *

Are you an existing collaborator, or have you previously collaborated with CSL (including CSL Behring, CSL Seqirus or CSL Vifor)?

Yes No

CONTINUE

Step 2/2 - Describe your opportunity and confirm submission

Please describe and categorize your opportunity.

Fields with * are mandatory

Proposal Title *

Primary Therapeutic Area *

Not specific to a Therapeutic Area (e.g. platform technology)

Secondary Therapeutic Area

Not specific to a Therapeutic Area (e.g. platform technology)

Indications *

Modality *

Cell therapy	Extracellular vesicles	Gene therapy
Oligonucleotide (siRNA, asRNA, ncRNA)	Peptide	Plasma
Recombinant (incl. antibodies)	Small molecule	Other modality

Opportunity Type *

Biomarker	New use for CSL product or pipeline candidate	Novel target or therapeutic candidate
Research Tool	Target Discovery	
Vaccines – mRNA/lipid nanoparticle platform improvements	Vaccines – influenza virus antigen purity/yield enhancements	
Vaccines – utilizing MF59® adjuvant	Other	

Project Description (max. 300 words) *

Example of what to include in Project Description: "We have discovered a novel target expressed on X cells. We have generated data in X assay(s) and/or X model(s). We have shown the mechanism of action is mediated via X pathway(s). Inhibition of this target could be used to treat X indication(s). This novel strategy could address an important unmet need for patients and be superior to standard of care and other therapeutics in development for reasons X, X and X."

I have read the privacy policy and agree with it. Read more... *

I hereby confirm that my submission does not contain any confidential information. *

I'm not a robot

BACK SUBMIT

Submission T&Cs on last slide

What makes for a competitive proposal?

- ✓ Aligned with our focus areas and modalities
- ✓ Project is clearly defined (as opposed to a general overview of the applicant's research interests)
- ✓ Focused on a novel target or therapeutic candidate
- ✓ Clear differentiation of approach from competitors and current standard of care
- ✓ Research team has capacity and expertise to complete the bulk of the experimental work over the course of the program (with CSL guidance and support)
- ✓ If third party IP is required, ensure your research organisation has secured all necessary rights to grant CSL an exclusive option to negotiate an exclusive, worldwide licence

CSL's core Therapeutic Areas



CSL's Core Therapeutic Areas & Platforms



R&D Portfolio – FY22

Immunology | Hematology | Respiratory | Cardiovascular & Metabolic | Vifor Pharma
Transplant | Influenza Vaccines | Outlicensed Programs | Partnered Projects

Phase I

- **CSL324** Anti-G-CSFR mAb (HS)
- **CSL730** rFc Multimer
- **CSL889** Hemopexin (SCD)
- **CSL787** Nebulised Ig
- **CSL311** Anti-Beta Common mAb
- **ASLAN004** Anti-IL-13R mAb (AD)
- **INS-3001** Oral calcification inhibitor (PAD, aortic valve stenosis)

Phase II

- **HIZENTRA®** (SSc)
- **Garadacimab** Anti-FXIIa mAb (ILD/IPF)
- **CSL346** Anti-VEGF-B mAb (DKD)
- **Adjuvanted Cell Culture Influenza Vaccine** (aQIVc)
- **Mavrilimumab** Anti-GM-CSFR mAb (GCA, COVID)
- **VIT-2763** Oral ferroportin inhibitor (Sickle cell disease)
- **VIT-2763** Oral ferroportin inhibitor (Beta-thalassemia)

Phase III

- **Garadacimab** Anti-FXIIa mAb (HAE)
- **HIZENTRA®** (DM)
- **EtranaDez** Etranacogene dezaparvovec (Hem B)
- **KCENTRA®** 4F-PCC (Trauma)
- **Sparsentan**[1] Dual ET_A & AT_1 antagonist (FSGS)
- **Sparsentan**[1] Dual ET_A & AT_1 antagonist (IgA Nephropathy)
- **CSL112** apoA-I (AMI)
- **Clazakizumab** Anti-IL-6 mAb (AMR)
- **CSL964** Alpha-1 Antitrypsin (Treatment of GvHD)
- **CSL964** Alpha 1 Antitrypsin (Prevention of GvHD)
- **SNF-472** Calcification inhibitor (CUA-ESRD)
- **SNF-472** Calcification inhibitor (PAD-ESRD)

1 Licensed from Travere Therapeutics, Inc.
2 Licensed from Cara Therapeutics, Inc.
3 Licensed from ChemoCentryx, Inc.
4 Licensed from OPKO Health, Inc.

Registration/Post-Registration

- **HAEGARDA®** (HAE)
- **HIZENTRA®** (SCIg) 20% Liquid
- **PRIVIGEN®** (IVIg) 10% Liquid
- **AFSTYLA®** rFVIII (Hem A)
- **IDELVION®** rFIX-FP (Hem B)
- **ZEMAIRA®/RESPREEZA®** Alpha-1 Antitrypsin
- **FOCLIVIA®/FOCETRIA** Adjuvanted Egg-based Influenza A (H5N1) Vaccine
- **VELTASSA** Oral potassium binder (Hyperkalemia)
- **KORSUVA/KAPRUVIA**[2] Kappa-opioid rec. agonist (CKD-aP)
- **AUDENZ™** Adjuvanted Monovalent Influenza A (H5N1) Vaccine
- **AFLURIA® QUAD** Egg-based Influenza Vaccine
- **FLUAD® Trivalent** Adjuvanted Influenza Vaccine
- **FLUAD® Quadrivalent** Adjuvanted Influenza Vaccine
- **FLUCELVAX® Quadrivalent** Cell-based Influenza Vaccine
- **PANVAX®** Egg-based Influenza Vaccine
- **TRAVENOS®**[3] Oral C5a receptor (ANCA associated vasculitis)
- **RAYALDEE®**[4] Oral calcifediol (Sec. hyperparathyroidism)

* Indicative of combined CSL/Vifor FY22 R&D portfolio assuming completion of acquisition.

Vadadustat licensed from Akebia Therapeutics, Inc.; Status pending - Complete Response Letter (CRL) received from FDA due to safety concerns.

Formal integration of Vifor's R&D programs into CSL's R&D portfolio will be subject to CSL's standard R&D portfolio review, management and integration processes.

Product and pipeline highlights

Privigen® (10% intravenous Ig)
Primary immunodeficiencies (PID), Secondary Immune Deficiency (SID)*, Chronic inflammatory demyelinating polyneuropathy (CIDP)

Hizentra® (20% subcutaneous Ig)
PID, CIDP, SID*
Dermatomyositis (DM), Ph III
Systemic sclerosis (SSc), Ph II

Haegarda® (C1 Esterase Inhibitor)
Hereditary angioedema

Garadacimab (Anti-FXIIa mAb)
Hereditary angioedema, Ph III

CSL324 (Anti-G-CSFR mAb)
Hidradenitis suppurativa (HS), Ph I

CSL730 (Recombinant Trivalent Human IgG1 Fc Multimer), Ph I

Gene Therapy Treatments
PID, Research

Idelvion® (Recombinant FIX-FP)
Hemophilia B

Afstyla® (Recombinant FVIII)
Hemophilia A

Kcentra® (Prothrombin complex concentrate)
Urgent warfarin reversal

HEMGENIX® (etranacogene dezaparvovec)
(AAV FIX gene therapy)
Hemophilia B, FDA approved

CSL889 (Hemopexin)
Sickle cell disease, Ph I

CSL888 (Haptoglobin)
Sub-arachnoid hemorrhage, preclinical development

ZEMAIRA®/RESPREEZA®
(Alpha 1 Antitrypsin)

Garadacimab (Anti-FXIIa mAb)
Idiopathic Pulmonary Fibrosis, Ph IIa

CSL311 (Anti-β-common mAb)
Airways inflammation, Ph I

CSL787 (Nebulised Ig)
Respiratory infections, Ph I



CSL112 (ApoA-1)
Acute coronary syndrome, Ph III

CSL346 (Anti-VEGFB mAb)
Diabetic kidney disease, Ph II

FLUAD Quadrivalent
Adjuvanted Influenza Vaccine

FLUCELVAX Quadrivalent
Cell-based Influenza Vaccine

Adjuvanted Cell Culture Influenza Vaccine (aQIVc), phase II

sa-mRNA Influenza Vaccine, PC

CSL964 (Alpha 1 Antitrypsin)
Graft versus host disease, Ph III

Clazakizumab (Anti-IL-6 mAb)
Antibody mediated rejection, Ph III

CSL040 (Novel Complement Inhibitor), PC

*ex-USA

Our full pipeline can be viewed here

Areas of interest for collaboration



2023 RAI Focus Areas

Autoimmune diseases (AID)

Novel targets or biologic therapies for the treatment of AIDs including primary Sjögren's syndrome, systemic sclerosis, inflammatory idiopathic myopathies (including dermatomyositis) and autoimmune skin blistering diseases

1. Novel immunomodulatory strategies targeting cytokines, chemokines, modulatory proteins and TNF-family members
2. Novel targets or biologic therapies involved in B cell depletion or B cell regulation
3. Novel targets or biologic therapies involved in T cell regulation, T cell tolerance and T regulatory cell modulation

Alternatives to plasma-derived intravenous immunoglobulin (IVIG)

Synthetic or recombinant solutions to IVIG that are independent of plasma

Hematology

2023 RAI Focus Areas

Hemorrhagic stroke

1. Novel biologic targets and therapies for the treatment of subarachnoid hemorrhage and intracerebral hemorrhage
2. Biomarker or omics approaches for patient stratification and drug discovery

Acute ischemic stroke

1. Novel biologic targets and therapies for the treatment of acute ischemic stroke, in particular anti-(thrombo-)inflammatory approaches as an adjunct to endovascular thrombectomy and pharmacological thrombolysis (tPA)
2. Biomarker or omics approaches for patient stratification and drug discovery

Acute thrombosis (venous and arterial thrombosis)

Novel biologic therapies for targeted fibrinolysis / thrombolysis with increased safety and/or efficacy vs. standard of care in acute thrombotic conditions, in particular acute ischemic stroke and pulmonary embolism

Respiratory

2023 RAI Focus Areas

Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)

1. Novel biologic therapies or targets to treat idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)
2. Omics approaches for patient stratification and drug discovery

Community acquired pneumonia (CAP)-associated complications

1. Novel biologic therapies or targets to treat community acquired pneumonia (CAP)-associated complications including acute respiratory distress syndrome (ARDS), sepsis, and acute kidney injury (AKI)
2. Omics approaches for patient stratification and drug discovery



Cardiovascular and Metabolic

2023 RAI Focus Areas

Myocarditis
Novel targets or biologic therapies for myocarditis

Dilated cardiomyopathy
Novel targets or biologic therapies for inflammatory dilated cardiomyopathy

Rare lipid disorders
Novel targets or biologic therapies (including gene therapies) for rare lipid disorders e.g. homozygous familial hypercholesterolemia

Severe forms of atherosclerosis
Novel targets or biologic therapies for severe atherosclerosis

Transplant

2023 RAI Focus Areas

Chronic lung allograft dysfunction (CLAD)

1. Novel biologic therapies or targets to prevent or treat CLAD, including approaches to establish tolerance / novel immunomodulation strategies
2. Novel biomarkers for CLAD

Hematopoietic stem cell transplant (HSCT)

1. Novel biologic therapies for the treatment and prevention of acute and chronic GvHD, including approaches to establish tolerance / novel immunomodulation strategies
2. Novel biologic therapies that improve efficacy / safety of HSCT

Cardiovascular allograft vasculopathy (CAV)

1. Novel biologic therapies for the treatment of CAV
2. Animal models of CAV

Vaccines

2023 RAI Focus Areas

mRNA and lipid nanoparticle platform
Innovative research addressing improved delivery, formulation, stabilisation (5°C / room temperature), shelf-life extension and manufacturing technologies

Influenza virus antigen purity and yield enhancement
Innovative research with potential to impact yield and purity of influenza virus HA antigen produced in MDCK cell culture

Proven adjuvant technology
Partnerships with our proprietary adjuvant MF59®

CSL's Areas of Interest for Platform Technologies

- *In vivo* kill switch or suicide switch
- Modulation of transgene expression *in vivo*
- Novel methods to select gene modified HSCs
- Novel therapeutic gene therapy targets aligned with CSL's Therapeutic Areas
- Non-viral *in vivo* delivery of RNPs

- Oral delivery of biologics
- MDCK cell culture yield improvements



- Antibodies
- Protein therapeutics
- LV gene therapies
- Cell therapies
- Structural vaccinology

*Areas **not** of interest*
- *Oncology (including hematological malignancies)*
- *Medical devices or diagnostics*
- *Small molecule approaches*

Benefits of collaborating with CSL



Capabilities from Discovery to Patients

Target Discovery



Translational Medicine & Data Science

Phase I / II Manufacturing

Patients

THERAPEUTIC PLATFORMS **CLINICAL STUDIES**



Animal Models of Disease

Toxicology & Product Development

Phase III / Launch Manufacturing

Benefits of collaborating with CSL

Global capabilities on your doorstep

Work with one of the world's leading biotech companies

Funding for successful proposals

Access to commercial, R&D, clinical, intellectual property, marketing and manufacturing expertise

Accelerate translation of your research to deliver new **therapies**

35 new partnerships established via the Research Acceleration Initiative since 2019

>200 active **Research collaborations**

170+ scientific papers published with our collaborators since 2020

SEVEN NEW CSL RESEARCH ACCELERATION INITIATIVE AWARDEES ANNOUNCED

7

Professor Allison Pettit
The University of Queensland, AUS

Dr Kirsten Coupland
University of Newcastle, AUS

Associate Professor Georgina Clark
ANZAC Research Institute, AUS

Professor Daniel Rader
University of Pennsylvania, USA

Professor Elie El Agha
Justus Liebig University Giessen, DE

Professor Arthur Liesz,
University Hospital of Ludwig Maximilian University of Munich, DE

Professor Daniel Ricklin
University of Basel, CH



Driven by Our Promise

CSL

Checklist for 2023 Research Acceleration Initiative

- Ensure your abstract is aligned with CSL's 2023 RAI focus areas (refer to flyer or slides 22-28)
- Connect with your TTO/BD/Commercialisation Office representative to discuss your abstract and to obtain the online abstract submission link
- Familiarise yourself with the abstract submission T&Cs (refer to last slide)
- Ensure no confidential information is disclosed in your abstract
- Submit your non-confidential 300 word abstract via the online portal by **23rd February 2023**
- CSL will provide feedback on the outcome of your abstract by 24th March 2023

Questions

THANK YOU

Dr Marthe D'Ombrain
Senior Director & Head,
Global Research Innovation

Marthe.Dombrain@csl.com.au

Dr Priscilla Hong
Manager, Research Innovation

Priscilla.Hong@csl.com.au

RAI@csl.com.au



Terms and Conditions for Research Acceleration Initiative Portal ("RAI Portal")

1. This RAI Portal is an online portal operated by CSL Innovation Pty Ltd ("CSL") for the purpose of allowing individuals to submit scientific proposals for consideration by CSL for its Research Acceleration Initiative program. By using this website and the RAI Portal, and by providing your submission and personal information to CSL, you are agreeing to abide by these terms and conditions.

2. You acknowledge and agree that CSL has no obligations of confidentiality or non-use in relation to the submission provided. You warrant that your submission does not contain confidential information of any kind. Further, you acknowledge that notwithstanding the existence of any confidentiality agreements previously entered into between you and CSL, the terms of such agreements will not apply with respect to any information submitted by you through the RAI Portal.

3. You further represent and warrant that:

- a. you have the right and authorisation (including where relevant after consultation with all relevant commercialisation or technology transfer offices) to submit an application to the RAI Portal and to accept the terms and conditions set out herein;
- b. you are an employee or are otherwise affiliated with a registered organisation authorised by CSL to submit an application to the RAI Portal; and
- c. to the best of your knowledge and without making any further enquiries, the information provided in your submission (and CSL's use of that information in connection with the Research Acceleration Initiative program) shall not infringe on the intellectual property rights of any third party, including your current or former employer, university, public research institute or other registered organisation.

4. CSL may disclose personal information collected in connection with your use of this website or the RAI Portal to your employer, university, public research institute or other registered organisation (if applicable) as at the time your application was submitted, solely for the purpose of reviewing and determining your application. CSL will ensure that any personal information collected, used or disclosed in connection with your use of this website or the RAI Portal is handled in accordance with all relevant privacy legislation and with CSL’s privacy policy, a copy of which is available at https://www.csl.com/privacy-policy.

5. CSL is under no obligation to respond to any individual application submitted to the RAI Portal, and may in its sole discretion choose not to progress an application further for any reason without any further communication with you.